Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates

Tullio Palmerini, Mark A. Nedelman, Lesley E. Scudder, Marian T. Nakada, Robert E. Jordan, Susan Smyth, Ronald E. Gordon, John T. Fallon, Barry S. Coller

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


OBJECTIVES. This study was designed to assess the effect of abciximab on platelet and leukocyte deposition 60 min after stent insertion in nonhuman primates. BACKGROUND. Although it is well established that abciximab improves both short- and long-term clinical outcomes after stent placement, there have been no studies assessing its effect on early platelet and leukocyte deposition. METHODS. Cynomolgus monkeys were pretreated with aspirin and either saline or a 0.4 mg/kg bolus of abciximab, and then subjected to angioplasty and Palmaz-Schatz stent placement in the common iliac artery or abdominal aorta. After 60 min, animals were euthanized and the stented artery was evaluated by immunohistochemistry and morphometry. RESULTS. Complete occlusion of the stented vessel with a thin fibrin(ogen) meshwork and trapped blood occurred in two saline-treated and two abciximab-treated animals. In the four remaining saline-treated animals, a layer of erythrocytes trapped in a network of fibrin(ogen) was noted close to the vessel wall, and this was covered by a layer of large, irregular platelet thrombi. Leukocytes formed a monolayer on top of the platelets and near stent struts. In the four remaining abciximab-treated animals, the mean erythrocyte area was 65% smaller (p = 0.070), the platelet aggregate area was 89% smaller (p = 0.049) and the luminal area was 59% larger (p = 0.004). A monolayer of leukocytes also formed on top of the platelets and near stent struts. CONCLUSIONS. In control stented blood vessels in this study, platelet thrombi formed not at the vessel wall, but on top of an erythrocyte-rich layer, and platelets recruited leukocytes. Abciximab decreased the size of platelet thrombi, but did not prevent leukocyte recruitment.

Original languageEnglish
Pages (from-to)360-366
Number of pages7
JournalJournal of the American College of Cardiology
Issue number2
StatePublished - Jul 17 2002

Bibliographical note

Funding Information:
Supported in part by grants 19278 and 54469 from the National Heart, Lung and Blood Institute and Centocor, Inc., Malvern, Pennsylvania. Dr. Coller is an inventor of abciximab and in accord with federal law and the policies of the Research Foundation of the State University of New York shares in payments made to the Foundation for the sales of abciximab.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates'. Together they form a unique fingerprint.

Cite this